Washington Summary July 2018

Department of Defense Peer Review Medical Research Program PKDF has asked Congress to return PKD to the list of eligible research programs under the Department of Defense’s Congressionally Directed Medical Research Program (CDMRP) and to designate $20 million...

Washington Summary May 2018

Tolvaptan (brand name JYNARQUE™) In April 2018, the FDA approved the first drug available in the US to treat ADPKD. Tolvaptan is a selective vasopressin V2-receptor antagonist. This means it blocks vasopressin, an anti-diuretic hormone secreted by the pituitary gland,...

Washington Summary April 2018

PKDF Priorities PKD Foundation is submitting its FY19 funding requests to the House and Senate Appropriations Committees. PKDF is asking Congress to return PKD to the list of eligible research programs under the Department of Defense’s Congressionally Directed Medical...

Washington Summary March 2018

Advocacy Alert Last week, the PKD Foundation asked its advocates to urge Congress to keep PKD on the list of eligible research programs for Fiscal Year 2018 under the Department of Defense’s Congressionally Directed Medical Research Program (CDMRP). Thank you to...

Tolvaptan and lixivaptan: what’s the difference?

In response to the news about lixivaptan’s orphan drug designation, there have been questions from the PKD community about the difference between the investigational drug and another potential ADPKD treatment, tolvaptan. Tolvaptan and lixivaptan are vasopressin...